First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Stopped Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.

Conditions

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukemia
• High-grade B-cell Lymphoma
• Primary Mediastinal Large B-cell Lymphoma

Interventions

• BIOLOGICAL: GEN3009
• BIOLOGICAL: Epcoritamab

Sponsor

Genmab